ADReCS

Pharmaceutical Information

Drug Name	Fluoxetine
Drug ID	BADD_D00932
Description	Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI).[A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.[L7721]
Indications and Usage	Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.[L7664]
Marketing Status	approved; vet_approved
ATC Code	N06AB03
DrugBank ID	DB00472
KEGG ID	D00326
MeSH ID	D005473
PubChem ID	3386
TTD Drug ID	D0TR5X
NDC Product Code	0093-0807; 43063-839; 53002-2305; 61919-869; 62332-243; 71335-0924; 0615-8093; 0093-7198; 50090-3180; 50111-647; 50228-421; 59651-308; 68645-130; 0615-7625; 72241-009; 0904-5785; 0904-7195; 49884-468; 55111-150; 59651-324; 62332-242; 65862-306; 71209-041; 61919-885; 63304-632; 72241-008; 80426-044; 63187-233; 63629-8179; 70518-3752; 71335-0565; 80425-0313; 59651-309; 13668-443; 46708-273; 68645-131; 80426-045; 23155-028; 23155-030; 42291-398; 42571-388; 62332-024; 63187-089; 71335-1048; 0904-5784; 23155-029; 42291-396; 42571-389; 62332-022; 72162-1506; 72241-007; 16714-112; 16714-113; 42291-397; 42571-387; 43598-566; 46708-272; 50228-420; 58118-0645; 70518-1619; 71209-042; 13668-473; 50111-648; 55154-1341; 61919-100; 62332-023; 63629-2201; 71205-178; 71205-188; 71209-040; 42708-025; 46708-271; 53002-5016
UNII	01K63SUP8D
Synonyms	Fluoxetine \| Fluoxetin \| N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine \| Lilly-110140 \| Lilly 110140 \| Lilly110140 \| Sarafem \| Fluoxetine Hydrochloride \| Prozac

Chemical Information

Molecular Formula	C17H18F3NO
CAS Registry Number	54910-89-3
SMILES	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Retinal detachment	06.09.03.003; 12.01.04.004	0.000020%
Retinal haemorrhage	06.10.01.001; 24.07.05.003	0.000020%		-
Retinopathy of prematurity	06.10.02.012; 12.02.02.015; 18.04.01.004	0.000020%		-
Retrograde ejaculation	21.03.01.006	0.000030%		-
Rhabdomyolysis	15.05.05.002	0.000177%
Rheumatoid arthritis	10.04.06.001; 15.01.03.001	-	-	-
Rhinitis	11.01.13.004; 22.07.03.006	-	-
Right ventricular failure	02.05.03.002	0.000020%		-
Salivary gland enlargement	07.06.03.002	-	-	-
Salivary hypersecretion	07.06.01.009	0.000030%		-
Salpingitis	11.01.10.001; 21.14.03.001	-	-	-
Scleritis	06.04.07.002; 10.02.01.025	-	-	-
Scoliosis	15.10.04.001	0.000049%
Screaming	08.01.03.099; 19.04.02.020	-	-	-
Seborrhoeic dermatitis	23.03.04.018	-	-	-
Secondary hypertension	24.08.02.015	0.000020%		-
Sedation	17.02.04.005	0.000155%		-
Seizure	17.12.03.001	0.000709%
Sensation of blood flow	08.01.09.031	0.000030%		-
Sensory disturbance	17.02.07.006	0.000049%		-
Sensory loss	17.02.07.007	-	-	-
Serotonin syndrome	12.03.01.041; 15.05.04.016; 17.05.02.004	0.001142%		-
Serum sickness	10.01.03.004; 12.02.08.004	0.000030%
Serum sickness-like reaction	08.01.03.003; 10.01.03.005	0.000059%		-
Sexual dysfunction	19.08.05.002; 21.03.02.003	0.000333%		-
Shock	24.06.02.002	-	-	-
Shock symptom	24.06.02.021	0.000030%		-
Sinus arrhythmia	02.03.03.008	0.000030%		-
Sinus bradycardia	02.03.03.009	0.000049%
Sinus tachycardia	02.03.03.010	0.000256%

The 21th Page First Pre 21 22 23 24 25 Next Last Total 35 Pages